Author

N. Hajdari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

E. E. Mulkearns-Hubert· 2 shared J. Lathia· 2 shared A. Huang· 1 shared A. Myers· 1 shared B. Weber· 1 shared C. Eng· 1 shared E. Downs-Kelly· 1 shared E. Esakov· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. E. Mulkearns-Hubert

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

VRK1 is a Paralog Synthetic Lethal Target in VRK2-methylated Glioblastoma

J. A. Shields, S. R. Meier, M. Bandi, M. Dam Ferdinez, J. L. Engel, E. E. Mulkearns-Hubert, N. Hajdari, K. Mitchell, W. Zhang, S.-c. Zhao, M. Zhang, R. Tjin Tham Sjin, E. Wilker, J. Lathia, J. Andersen, , N. Emmanuel

This study identifies VRK1 as a synthetic lethal target in VRK2-methylated glioblastoma by showing that VRK1 inhibition leads to tumor growth inhibition in xenograft models.

bioRxiv · Dec 30, 2021 · PreprintCancer Biology

Targeting the Cx26/NANOG/Focal Adhesion Kinase Complex via Cell Penetrating Peptides in Triple Negative Breast Cancers

E. E. Mulkearns-Hubert, E. Esakov, S. Ben-Salem, R. Bharti, N. Hajdari, S. Johnson, A. Myers, I. N. Smith, S. Bandyopadhyay, C. Eng, E. Downs-Kelly, J. Lathia, O. Reizes

This study demonstrates that a cell-penetrating peptide targeting the Cx26/NANOG/FAK complex inhibits tumor growth and alters NANOG activity in triple-negative breast cancer.

bioRxiv · Sep 9, 2021 · PreprintCancer Biology